表紙
市場調査レポート

動脈血栓症:パイプライン製品の分析

Arterial Thrombosis - Pipeline Review, H1 2016

発行 Global Markets Direct 商品コード 293894
出版日 ページ情報 英文 61 Pages
即納可能
価格
本日の銀行送金レート: 1USD=105.42円で換算しております。
Back to Top
動脈血栓症:パイプライン製品の分析 Arterial Thrombosis - Pipeline Review, H1 2016
出版日: 2016年03月30日 ページ情報: 英文 61 Pages
概要

動脈血栓症とは動脈上に発生する血餅であり、脈拍欠損、筋痛、筋痙攣、皮膚蒼白、冷感といった症状があります。血餅の発生場所により、脳卒中、心臓発作、末梢動脈疾患 (PAD) など、さまざまな重篤な症状を引き起こします。喫煙や肥満、糖尿病、高血圧、高コレステロールなどが素因となる要素であり、血栓溶解薬や手術といった治療法があります。

当レポートでは、世界における動脈血栓症治療薬のパイプラインについて取り上げ、現在の開発パイプラインの状況や最新動向、薬剤プロファイル、主要企業および開発中の製品レビューなどをお届けいたします。

イントロダクション

  • 調査範囲

動脈血栓症の概要

治療薬の開発

  • パイプライン製品の概要
  • パイプライン製品の比較分析

動脈血栓症:開発中の治療薬:企業別

動脈血栓症:開発中の治療薬:大学・研究機関別

動脈血栓症:パイプライン製品の概況

  • 後期段階の製品
  • 臨床段階の製品
  • 初期段階の製品

動脈血栓症:開発中の製品:企業別

動脈血栓症:開発中の製品:大学・研究機関別

動脈血栓症:治療薬開発に従事している企業

  • Arena Pharmaceuticals, Inc.
  • アステラス製薬
  • AstraZeneca Plc
  • Bayer AG
  • Bristol-Myers Squibb Company
  • エーザイ
  • Johnson & Johnson
  • Sanofi

動脈血栓症:治療薬の評価

  • 単剤製品
  • 標的別
  • 作用機序別
  • 投与経路別
  • 分子タイプ別

薬剤プロファイル

  • AS-1468240
  • ASP-1645
  • ASP-6537
  • BAY-1213790
  • BMS-593214
  • BMS-654457
  • C-3
  • E-5539
  • ER-410660
  • JNJ-375
  • 動脈血栓症・肺血栓塞栓症のためのPAI-1阻害ペプチド
  • PZ-128
  • SAR-216471
  • テマノグレル塩酸塩
  • チカグレロル
    • 製品概要
    • 作用機序
    • R&Dの進捗

動脈血栓症:最近のパイプライン動向

動脈血栓症:休止中のプロジェクト

動脈血栓症:製品開発のマイルストーン

  • 主なニュースとプレスリリース

付録

図表

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: GMDHC7739IDB

Summary

Global Markets Direct's, 'Arterial Thrombosis - Pipeline Review, H1 2016', provides an overview of the Arterial Thrombosis pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Arterial Thrombosis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Arterial Thrombosis and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Arterial Thrombosis
  • The report reviews pipeline therapeutics for Arterial Thrombosis by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved Arterial Thrombosis therapeutics and enlists all their major and minor projects
  • The report assesses Arterial Thrombosis therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news related to pipeline therapeutics for Arterial Thrombosis

Reasons to buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for Arterial Thrombosis
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Arterial Thrombosis pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Arterial Thrombosis Overview
  • Therapeutics Development
    • Pipeline Products for Arterial Thrombosis - Overview
    • Pipeline Products for Arterial Thrombosis - Comparative Analysis
  • Arterial Thrombosis - Therapeutics under Development by Companies
  • Arterial Thrombosis - Therapeutics under Investigation by Universities/Institutes
  • Arterial Thrombosis - Pipeline Products Glance
    • Late Stage Products
    • Clinical Stage Products
    • Early Stage Products
  • Arterial Thrombosis - Products under Development by Companies
  • Arterial Thrombosis - Products under Investigation by Universities/Institutes
  • Arterial Thrombosis - Companies Involved in Therapeutics Development
    • Astellas Pharma Inc.
    • AstraZeneca Plc
    • Bayer AG
    • Bristol-Myers Squibb Company
    • Eisai Co., Ltd.
    • Johnson & Johnson
    • Sanofi
  • Arterial Thrombosis - Therapeutics Assessment
    • Assessment by Monotherapy Products
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Drug Profiles
    • AS-1468240 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • ASP-1645 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • ASP-6537 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • BAY-1213790 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • BMS-593214 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • BMS-654457 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • C-3 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • E-5539 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • ER-410660 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • JNJ-375 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Peptide to Inhibit PAI-1 for Arterial Thrombosis and Pulmonary Thromboembolism - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • PZ-128 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • SAR-216471 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • ticagrelor - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • Arterial Thrombosis - Recent Pipeline Updates
  • Arterial Thrombosis - Dormant Projects
  • Arterial Thrombosis - Product Development Milestones
    • Featured News & Press Releases
      • Nov 13, 2014: AstraZeneca announces initiation of development programme for BRILINTA reversal agent
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for Arterial Thrombosis, H1 2016
  • Number of Products under Development for Arterial Thrombosis - Comparative Analysis, H1 2016
  • Number of Products under Development by Companies, H1 2016
  • Number of Products under Investigation by Universities/Institutes, H1 2016
  • Comparative Analysis by Late Stage Development, H1 2016
  • Comparative Analysis by Clinical Stage Development, H1 2016
  • Comparative Analysis by Early Stage Development, H1 2016
  • Products under Development by Companies, H1 2016
  • Products under Investigation by Universities/Institutes, H1 2016
  • Arterial Thrombosis - Pipeline by Astellas Pharma Inc., H1 2016
  • Arterial Thrombosis - Pipeline by AstraZeneca Plc, H1 2016
  • Arterial Thrombosis - Pipeline by Bayer AG, H1 2016
  • Arterial Thrombosis - Pipeline by Bristol-Myers Squibb Company, H1 2016
  • Arterial Thrombosis - Pipeline by Eisai Co., Ltd., H1 2016
  • Arterial Thrombosis - Pipeline by Johnson & Johnson, H1 2016
  • Arterial Thrombosis - Pipeline by Sanofi, H1 2016
  • Assessment by Monotherapy Products, H1 2016
  • Number of Products by Stage and Target, H1 2016
  • Number of Products by Stage and Mechanism of Action, H1 2016
  • Number of Products by Stage and Route of Administration, H1 2016
  • Number of Products by Stage and Molecule Type, H1 2016
  • Arterial Thrombosis Therapeutics - Recent Pipeline Updates, H1 2016
  • Arterial Thrombosis - Dormant Projects, H1 2016

List of Figures

  • Number of Products under Development for Arterial Thrombosis, H1 2016
  • Number of Products under Development for Arterial Thrombosis - Comparative Analysis, H1 2016
  • Number of Products under Development by Companies, H1 2016
  • Number of Products under Investigation by Universities/Institutes, H1 2016
  • Comparative Analysis by Clinical Stage Development, H1 2016
  • Comparative Analysis by Early Stage Products, H1 2016
  • Assessment by Monotherapy Products, H1 2016
  • Number of Products by Targets, H1 2016
  • Number of Products by Stage and Targets, H1 2016
  • Number of Products by Mechanism of Actions, H1 2016
  • Number of Products by Stage and Mechanism of Actions, H1 2016
  • Number of Products by Routes of Administration, H1 2016
  • Number of Products by Stage and Routes of Administration, H1 2016
  • Number of Products by Molecule Types, H1 2016
  • Number of Products by Stage and Molecule Types, H1 2016
Back to Top